{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-059999","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.469636+00:00","generated_at":"2026-06-18T13:05:48.701113+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Graybug Vision discloses supplemental merger details, CMO Parisa Zamiri terminated ahead of CalciMedica merger","bullets":["CMO Parisa Zamiri terminated Feb 28, 2023; receives $829,084 severance, COBRA, and stock acceleration.","Zamiri also signed consulting agreement at $350/hr up to 8 hrs/week through May 21, 2023.","Supplemental disclosures include corrected CalciMedica financial projections (revenue starting FY2028) and Piper Sandler analysis.","Piper Sandler to receive $3M fee for merger advisory; $100K retainer and $750K opinion fee already earned.","Four stockholder lawsuits and nine demand letters allege proxy statement omissions; Graybug believes claims without merit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-059999","json":"https://secwatch.observer/filing/0001193125-23-059999.json","markdown":"https://secwatch.observer/filing/0001193125-23-059999.md","text":"https://secwatch.observer/filing/0001193125-23-059999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523059999/0001193125-23-059999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523059999/d424298d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:05:48.701113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd62c5f445","claim":"Parisa Zamiri was terminated as Chief Medical Officer at CalciMedica, Inc..","evidence_excerpt":"On February 28, 2023, the Board of Directors of Graybug Vision, Inc. (“Graybug”) determined it to be in Graybug’s best interests to terminate Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523059999/0001193125-23-059999-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}